Bicycle therapeutics announces closing of public offering of american depositary shares and non-voting ordinary shares and full exercise of underwriters' option to purchase additional shares

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the closing on monday, july 17, 2023 of its underwritten public offering of 6,117,648 american depositary shares (“adss”), each representing one ordinary share, which includes 1,411,764 adss sold upon the underwriters' full exercise of their option.
BCYC Ratings Summary
BCYC Quant Ranking